28.27
前日終値:
$25.65
開ける:
$25.61
24時間の取引高:
24.81M
Relative Volume:
0.66
時価総額:
$6.53B
収益:
$2.35B
当期純損益:
$128.37M
株価収益率:
54.15
EPS:
0.5221
ネットキャッシュフロー:
$57.42M
1週間 パフォーマンス:
+3.14%
1か月 パフォーマンス:
+45.80%
6か月 パフォーマンス:
-31.10%
1年 パフォーマンス:
-45.00%
Hims Hers Health Inc Stock (HIMS) Company Profile
Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
HIMS
Hims Hers Health Inc
|
28.27 | 6.53B | 2.35B | 128.37M | 57.42M | 0.5221 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.46 | 52.00B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.73 | 41.60B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
9.11 | 40.43B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
82.83 | 34.72B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
UTHR
United Therapeutics Corp
|
564.94 | 23.98B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-24 | 開始されました | JP Morgan | Overweight |
| 2026-03-10 | アップグレード | BofA Securities | Underperform → Neutral |
| 2026-03-10 | アップグレード | Citigroup | Sell → Neutral |
| 2026-03-09 | アップグレード | Needham | Hold → Buy |
| 2026-02-24 | ダウングレード | BTIG Research | Buy → Neutral |
| 2026-01-12 | 開始されました | Evercore ISI | In-line |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-21 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | ダウングレード | Needham | Buy → Hold |
| 2025-06-04 | 繰り返されました | Needham | Buy |
| 2025-04-29 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
Hims & Hers Stock (HIMS) Faces a GLP-1 Test as Q1 Earnings Loom - TechStock²
Hims & Hers Health Inc (HIMS) Stock Up 10.2% and Still Undervalued -- GF Score: 75/100 - GuruFocus
Hims & Hers Health (HIMS) Set to Report Q1 Earnings with Mixed E - GuruFocus
Hims Stock Faces 15% Earnings Swing as Weight-Loss Pivot Comes Due - TechStock²
HIMS Stock Slides After Amazon Escalates GLP-1 War With Ozempic — AI Healthcare Bets In Focus Ahead Of Earnings - Stocktwits
Can Platform Expansion Support Hims & Hers Stock Before Q1 Earnings? - Yahoo Finance
Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus - Investing.com
Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus - MarketBeat
Hims & Hers launches AI agent for lab results - TechTarget
Hims adds AI for lab insights - eMarketer
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims - MarketBeat
Meet Labs AI: The First AI Care Agent from Hims & Hers - Hims & Hers Newsroom
Hims & Hers Health stock price forecast: $27.22 resistance in focus as HIMS rises 2.09% - Traders Union
Investor relations - HIMS Investor Relations
EDGAR Filing Documents for 0001773751-26-000060 - SEC.gov
Hims & Hers Health stock drops 3.45% as sharp selling follows early gap down - Traders Union
Stocks Under $50 to Buy or Avoid in May 2026: Hims & Hers, Insteel, Helix EnergyNews and Statistics - IndexBox
Hims & Hers Health, Inc. (HIMS) stock drops despite market gains: Important facts to note - MSN
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Hims & Hers Expands DTC Platform to Broaden Access to Personal Care - The Globe and Mail
HIMS Stock Jumps Overnight: CEO Eyes Heart Attack Prediction Firm With ‘Unreal’ Value - Stocktwits
Hims Earnings: Stability Could Trigger A Squeeze (NYSE:HIMS) - Seeking Alpha
Muted trading for Hims & Hers stock as price tests $26.60 support - Traders Union
Hims & Hers Health Options Spot-On: On May 4th, 110.86K Contracts Were Traded, With 1.24 Million Open Interest - Moomoo
HIMS Faces High Short Interest at 31.78% Amid Bearish Sentiment in Healthcare Sector - GuruFocus
Hims & Hers Health, Inc. (HIMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Most and least shorted mid-to mega-cap healthcare stocks in May - Seeking Alpha
Hims & Hers Health stock holds steady amid support level containing downside moves - Traders Union
Bronstein, Gewirtz & Grossman, LLC Is Investigating Hims & Hers Health, Inc. (HIMS) And Encourages Investors to Connect - ACCESS Newswire
Russell 2000 Analysis: Two Stocks Face Headwinds, One Potential Outperformer - IndexBox
Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now? - Insider Monkey
2026-05-03 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Hims & Hers Health, Inc. (HIMS) And Encourages Investors to Connect | NYSE:HIMS | Press Release - Stockhouse
Hims & Hers Is Down 7% After FDA Proposes New GLP-1 Drug Rules. Here’s What Investors Should Know - TIKR.com
A Look At Hims & Hers Health (HIMS) Valuation As Competition And Legal Risks Intensify - simplywall.st
Hims & Hers Health, Inc. (Derivatives): Latest News, Social Media Updates and Insights - CryptoRank
Data Breach Lawsuits Test Hims And Hers Health Valuation And Momentum - Yahoo Finance
HIMS Stock | Hims & Hers Health Price, Quote, News & Analysis - TipRanks
Hims, Hims & Hers class actions allege data breach exposed sensitive patient information - Class Action Lawsuits
Hims & Hers, Novo Nordisk: FDA GLP-1 Compounding Ruling May Actually Favor Hims (NYSE:NVO) - Seeking Alpha
+3.19% for Hims & Hers Health stock as gap higher shifts short-term outlook - Traders Union
HIMS Stock On The Mend? New Testosterone Push Builds As GLP-1 Gold Rush Gets Crowded - Stocktwits
Hims & Hers Health, Inc. (HIMS) is a top-ranked momentum stock: Should you buy? - MSN
HIMS vs. TDOC: Which Digital Health Stock Offers Better Upside Now? - The Globe and Mail
Hims & Hers Health stock price forecast: $25.00 support in focus as HIMS falls 5.66% - Traders Union
Hims & Hers Health, Inc. (NYSE:HIMS) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Hims & Hers Expands Digital-First Access to Personalized Healthcare - The Globe and Mail
Hims & Hers Health shares dip amid rising selling pressure - Traders Union
Hims & Hers Health, Inc. (HIMS) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Hims & Hers Health, Inc. (Derivatives) Analytics: Price Dynamics, Quarterly Returns, and Annual Price Changes in USD - CryptoRank
Hims & Hers Health, Inc. (Derivatives) Exchanges HIMS Markets | Buy & Sell & Trade - CryptoRank
Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today - Yahoo Finance
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
Hims Hers Health Inc (HIMS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Okupe Oluyemi | Chief Financial Officer |
Apr 20 '26 |
Option Exercise |
8.65 |
12,553 |
108,531 |
282,599 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 20 '26 |
Sale |
29.96 |
19,645 |
588,615 |
262,954 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 17 '26 |
Option Exercise |
5.01 |
6,184 |
30,982 |
288,051 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 16 '26 |
Sale |
25.90 |
36,922 |
956,147 |
281,867 |
| Okupe Oluyemi | Chief Financial Officer |
Apr 17 '26 |
Sale |
27.83 |
18,005 |
501,158 |
270,046 |
大文字化:
|
ボリューム (24 時間):